Form 8-K - Current report:
SEC Accession No. 0001999371-25-001105
Filing Date
2025-02-03
Accepted
2025-02-03 08:05:23
Documents
15
Period of Report
2025-02-03
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_020325.htm   iXBRL 8-K 51614
2 PAY-OFF LETTER DATED FEBRUARY 3, 2025 ex10-01.htm EX-10.01 56334
3 PRESS RELEASE ex99-01.htm EX-99.01 30635
  Complete submission text file 0001999371-25-001105.txt   334753

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnxp-20250203.xsd EX-101.SCH 3024
5 XBRL LABEL FILE tnxp-20250203_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tnxp-20250203_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_020325_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 25580685
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)